OurPath (rebranded as Second Nature) is a UK digital health company that builds a behavioral-change weight‑loss and diabetes‑prevention program delivered via app plus human coaching and connected tracking devices; it has been commissioned by the NHS and has raised venture funding while scaling internationally[1][3].
High‑Level Overview
- Mission: To enable lasting habit change to prevent and reverse type‑2 diabetes and obesity‑related conditions by combining behavioral science, human coaching, and digital tracking[1][3].
- Investment philosophy (if treated as an investable business): OurPath attracted early-stage investors focused on mission‑driven health tech, including Connect Ventures, SpeedInvest, Beringea and angel backers, signaling a preference for evidence‑based digital therapeutics that can partner with public health systems[1][3].
- Key sectors: Digital health / digital therapeutics, preventive care, weight management, chronic disease management (type‑2 diabetes)[1][3].
- Impact on the startup ecosystem: Helped validate scalable, clinically oriented weight‑loss/behavioral‑change programs in the UK market, demonstrated a route to NHS contracting, and provided a model for combining tech with clinician-led support that other health startups have emulated[1][3].
Origin Story
- Founding year and founders: OurPath was founded circa 2015 by healthcare‑strategy consultants Chris Edson and Mike Gibbs; both are Oxbridge alumni who designed the programme to deliver intensive lifestyle support to change behaviour[1][3].
- How the idea emerged: The founders experienced rising NHS strain from lifestyle disease and built a data‑driven programme combining dietitian support, peer‑group digital support, and Bluetooth‑connected tracking to create sustained habit change and reduce type‑2 diabetes risk[1][3].
- Early traction / pivotal moments: Early commissioning by the NHS (available by GP prescription in the UK) was a major validation; a $3M seed/early round led by Connect Ventures in 2018 funded UK growth and hiring[1]. The company later rebranded to Second Nature and closed a $10M Series A led by Beringea while scaling beyond 15,000 customers[3].
Core Differentiators
- Evidence‑driven, clinician‑led program: Combines dietitians and health experts with behavioral science rather than offering only algorithmic coaching[1][3].
- Hybrid human + tech model: Mobile app and Bluetooth‑enabled tracking hardware integrated with human coaching and peer support groups to drive adherence and habit formation[1][3].
- NHS contracting and clinical credibility: Secured NHS commissioning and GP prescription routes in the UK, demonstrating public‑sector acceptance uncommon for early digital health startups[1].
- Fundraising and investor network: Early backing from Connect Ventures, SpeedInvest, prominent angels (e.g., Taavet Hinrikus, Ian Hogarth), and later Series A from Beringea provided both capital and credibility for scaling[1][3].
- Rebrand and scale readiness: Transition to Second Nature signaled a shift from a narrow diabetes‑reversal framing toward broader habit‑change, enabling international expansion and diversified customer acquisition[3].
Role in the Broader Tech Landscape
- Trend alignment: Rides the convergence of digital therapeutics, remote monitoring, and preventative care—areas growing as health systems seek scalable, lower‑cost interventions for chronic disease[1][3].
- Timing: Rising prevalence of obesity and type‑2 diabetes, plus strained public healthcare budgets, created demand for scalable, evidence‑based preventative programs that can lower long‑term costs[3].
- Market forces: Public payers (e.g., NHS) and employers are increasingly willing to fund digital health programs with measurable outcomes, favoring companies that demonstrate clinical effect and cost savings[1][3].
- Influence: Helped demonstrate a commercially viable path for digital behavior‑change programs to work with national health systems and attract traditional VC and impact‑oriented investors.
Quick Take & Future Outlook
- What’s next: Continued international expansion, broader positioning as a general habit‑change/weight‑management platform (beyond strict diabetes reversal), and deeper integration with healthcare payers and employers are likely growth levers given the company’s rebrand and Series A funding[3].
- Trends that will shape them: Greater payer reimbursement for digital therapeutics, tighter clinical evidence requirements, competition from other DTx players, and increased demand for integrated remote‑care solutions will determine pace and scale of adoption.
- How influence might evolve: If OurPath/Second Nature sustains strong clinical outcomes and cost‑savings data, it could become a standard digital-first pathway for obesity and prediabetes management within public and private healthcare contracts, influencing reimbursement models and behavior‑change program design[1][3].
Quick final note: reporting treats OurPath and Second Nature as the same entity—OurPath rebranded to Second Nature while raising a Series A and expanding its mission from diabetes reversal toward broader habit change[3].
